[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.209.104.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
September 2015

Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is Due

Author Affiliations
  • 1Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
JAMA Oncol. 2015;1(6):795-796. doi:10.1001/jamaoncol.2015.1789

For decades, effective treatment for metastatic colorectal cancer (mCRC) was an almost impenetrable obstacle, with a single therapeutic option—fluorouracil. Outcomes were highly consistent across time and across trials, with a median overall survival (OS) of approximately 1 year. The last 20 years have seen highly clinically relevant improvements in not only OS but also progression-free survival (PFS) and response rates. In the most recently reported large first-line randomized trials, median OS has reached or exceeded 30 months.1

×